Different Dose of Intravenous Omeprazole to Treat Bleeding Ulcer With Adherent Clot
Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
The investigators will include those patients with adherent clot on gastric or duodenal
ulcers after endoscopic confirmation After receiving well explanation and giving written
consent, they are enrolled and will be allocated to 2 groups randomly. Those in the first
group will receive intravenous omeprazole 40 mg stat and then 40 mg q12h. Those in the second
group will receive intravenous omeprazole 80 mg stat and then 8mg/hr infusion. The patients
in both groups will receive intravenous omeprazole for 3 days and then oral esomeprazole qd
for further treatment of peptic ulcer.
The investigators define rebleeding during admission and within 30 days as primary end points
and define surgical intervention for ulcer bleeding, transfusion amount and hospitalization
days after allocation as secondary end points.